Literature DB >> 6223938

Single-strain regression analysis for determination of interpretive breakpoints for cefoperazone disk diffusion susceptibility testing.

G Kronvall.   

Abstract

A novel approach for setting interpretive breakpoints in disk diffusion antibiotic susceptibility testing according to determined minimum inhibitory concentration (MIC) limits is described, using the method of single-strain regression analysis. The procedure was tested on reference strains Staphylococcus aureus (ATCC 25923), Streptococcus faecalis (ATCC 29212), Escherichia coli (ATCC 25922), and Pseudomonas aeruginosa (ATCC 27853), using published results from cefoperazone disk diffusion experiments. The correlation between logarithm of the disk content and inhibition zone diameter squared was linear, excluding three endpoint values. When constants A and B in the new regression line equation were calculated for the four strains, all four showed different regression lines. Zone diameters corresponding to various MICs were calculated for a disk content of 75 micrograms. The values obtained for the four strains were 20.1, 20.9, 24.9, and 25.8 mm, respectively, for an MIC of 16 micrograms/ml, and 15.7, 15.7, 22.3, and 17.9 mm, respectively, for an MIC of 64 micrograms/ml. The following zone diameter breakpoints were determined for the "I" (intermediate) category, using a 75-micrograms disk: S. aureus, 18 to 15 mm; S. faecalis, 23 to 13 mm; E. coli, 20 to 17 mm; and P. aeruginosa, 20 to 17 mm.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223938      PMCID: PMC272786          DOI: 10.1128/jcm.17.6.975-980.1983

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

2.  Computer-generated plots of results of antimicrobial-susceptibility tests.

Authors:  T F O'Brien; R L Kent; A A Medeiros
Journal:  JAMA       Date:  1969-10-06       Impact factor: 56.272

3.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

4.  Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study.

Authors:  T L Gavan; R N Jones; A L Barry; P C Fuchs; E H Gerlach; J M Matsen; L B Reller; C Thornsberry; L D Thrupp
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

5.  [Improved bacterial resistance testing by a standardized SIR-system].

Authors:  G Kronvall; A Runehagen
Journal:  Lakartidningen       Date:  1981-09-30

6.  Interpretation of agar diffusion tests.

Authors:  C Krasemann; G Hildenbrand
Journal:  J Antimicrob Chemother       Date:  1980-03       Impact factor: 5.790

7.  Quality control of agar diffusion susceptibility tests.

Authors:  R C Knowles; T D Moore
Journal:  Am J Clin Pathol       Date:  1979-08       Impact factor: 2.493

8.  Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

9.  Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.

Authors:  R N Jones; T L Gavan; A L Barry; C Thornsberry; D L Gibbs
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

10.  Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone.

Authors:  C Thornsberry; A L Barry; R N Jones; C N Baker; R E Badal
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.